5-HT2A receptor explained

The 5-HT2A receptor is a subtype of the 5-HT2 receptor that belongs to the serotonin receptor family and is a G protein-coupled receptor (GPCR).[1] The 5-HT2A receptor is a cell surface receptor,[2] but has several intracellular locations.[3]

Like all 5-HT2 receptors, the 5-HT2A receptor is Gq/G11-protein coupled. This is the main excitatory receptor subtype among the GPCRs for serotonin, although 5-HT2A may also have an inhibitory effect[4] on certain areas such as the visual cortex and the orbitofrontal cortex.[5] This receptor was first noted for its importance as a target of serotonergic psychedelic drugs such as LSD and psilocybin mushrooms. Later it came back to prominence because it was also found to be mediating, at least partly, the action of many antipsychotic drugs, especially atypical antipsychotics.

Downregulation of post-synaptic 5-HT2A receptor is an adaptive process provoked by chronic administration of selective serotonin reuptake inhibitors (SSRIs) and atypical antipsychotics. Suicidal and otherwise depressed patients have had more 5-HT2A receptors than normal patients. These findings suggest that post-synaptic 5-HT2A overdensity is involved in the pathogenesis of depression.[6]

Paradoxical down-regulation of 5-HT2A receptors can be observed with several 5-HT2A antagonists.[7] Thus, instead of tolerance, reverse-tolerance would be expected from 5-HT2A antagonists. However, there is at least one antagonist at this site which has been shown to up-regulate 5-HT2A receptors.[8] Additionally, a couple of other antagonists may have no effect on 5-HT2A receptor number.[9] Nevertheless, upregulation is the exception rather than the rule. Neither tolerance nor rebound is observed in humans with regard to the slow-wave sleep (SWS) promoting effects of 5-HT2A antagonists.[10]

Signaling cascade

The 5-HT2A receptor is known primarily to couple to the Gαq signal transduction pathway. Upon receptor stimulation with agonist, Gαq and β-γ subunits dissociate to initiate downstream effector pathways. Gαq stimulates phospholipase C (PLC) activity, which subsequently promotes the release of diacylglycerol (DAG) and inositol triphosphate (IP3), which in turn stimulate protein kinase C (PKC) activity and Ca2+ release.[11]

History

5-HT receptors were split into two classes by John Gaddum and Picarelli when it was discovered that some of the serotonin-induced changes in the gut could be blocked by morphine, while the remainder of the response was inhibited by dibenzyline, leading to the naming of M and D receptors, respectively. 5-HT2A is thought to correspond to what was originally described as D subtype of 5-HT receptors by Gaddum and Picarelli.[12] In the era before molecular cloning, when radioligand binding and displacement was the only major tool, spiperone and LSD were shown to label two different 5-HT receptors, and neither of them displaced morphine, leading to naming of the 5-HT1, 5-HT2 and 5-HT3 receptors, corresponding to high affinity sites from LSD, spiperone and morphine, respectively.[13] Later it was shown that the 5-HT2 was very close to 5-HT1C and thus were grouped together, renaming the 5-HT2 into 5-HT2A. Thus, the 5-HT2 receptor family is composed of three separate molecular entities: the 5-HT2A (formerly known as 5-HT2 or D), the 5-HT2B (formerly known as 5-HT2F) and the 5-HT2C (formerly known as 5-HT1C) receptors.[14]

Distribution

5-HT2A is expressed widely throughout the central nervous system (CNS).[15] It is expressed near most of the serotonergic terminal rich areas, including neocortex (mainly prefrontal, parietal, and somatosensory cortex) and the olfactory tubercle. Especially high concentrations of this receptor on the apical dendrites of pyramidal cells in layer V of the cortex may modulate cognitive processes, working memory, and attention[16] [17] [18] by enhancing glutamate release followed by a complex range of interactions with the 5-HT1A,[19] GABAA,[20] adenosine A1,[21] AMPA,[22] mGluR2/3,[23] mGlu5,[24] and OX2 receptors.[25] [26] In the rat cerebellum, the protein has also been found in the Golgi cells of the granular layer,[27] and in the Purkinje cells.[28] [29]

In the periphery, it is highly expressed in platelets and many cell types of the cardiovascular system, in fibroblasts, and in neurons of the peripheral nervous system. Additionally, 5-HT2A mRNA expression has been observed in human monocytes.[30] Whole-body distribution of the 5-HT2A/2C receptor agonist, [11C]Cimbi-36 show uptake in several internal organs and brown adipose tissue (BAT), but it is not clear if this represents specific 5-HT2A receptor binding.[31]

Effects

Physiological processes mediated by the receptor include:

Ligands

Agonists

Activation of the 5-HT2A receptor is necessary for the effects of the "classic" psychedelics like LSD, psilocin and mescaline, which act as full or partial agonists at this receptor, and represent the three main classes of 5-HT2A agonists, the ergolines, tryptamines and phenethylamines, respectively. A very large family of derivatives from these three classes has been developed, and their structure-activity relationships have been extensively researched.[45] [46] Agonists acting at 5-HT2A receptors located on the apical dendrites of pyramidal cells within regions of the prefrontal cortex are believed to mediate hallucinogenic activity. Some findings reveal that psychoactive effects of classic psychedelics are mediated by the receptor heterodimer 5-HT2A–mGlu2 and not by monomeric 5-HT2A receptors.[47] [48] [32] However, newer research suggests that 5HT2A and mGlu2 receptors do not physically associate with each other, so the former findings have questionable relevance.[49] Agonists enhance dopamine in PFC,[18] enhance memory and play an active role in attention and learning.[50] [51]

Full agonists

Partial agonists

Peripherally selective agonists

One effect of 5-HT2A receptor activation is a reduction in intraocular pressure, and so 5-HT2A agonists can be useful for the treatment of glaucoma. This has led to the development of compounds such as AL-34662 that are hoped to reduce pressure inside the eyes but without crossing the blood–brain barrier and producing hallucinogenic side effects.[77] Animal studies with this compound showed it to be free of hallucinogenic effects at doses up to 30 mg/kg, although several of its more lipophilic analogues did produce the head-twitch response known to be characteristic of hallucinogenic effects in rodents.[78]

Antagonists

Antagonists and cardiovascular disease

Increased 5-HT2A expression is observed in patients with coronary thrombosis, and the receptor has been associated with processes that influence atherosclerosis.[90] As the receptor is present in coronary arteries[91] and capable of mediating vasoconstriction, 5-HT2A has also been linked to coronary artery spasms.[92] 5-HT antagonism, therefore, has potential in the prevention of cardiovascular disease, however, no studies have been published so far.[90]

Inverse agonists

Functional selectivity

5-HT2A-receptor ligands may differentially activate the transductional pathways (see above). Studies evaluated the activation of two effectors, PLC and PLA2, by means of their second messengers. Compounds displaying more pronounced functional selectivity are 2,5-DMA and 2C-N. The former induces IP accumulation without activating the PLA2 mediated response, while the latter elicits AA release without activating the PLC mediated response.[101]

Recent research has suggested potential signaling differences within the somatosensory cortex between 5-HT2A agonists that produce headshakes in the mouse and those that do not, such as lisuride, as these agents are also non-hallucinogenic in humans despite being active 5-HT2A agonists.[102] [103] One known example of differences in signal transduction is between the two 5-HT2A agonists serotonin and DOI that involves differential recruitment of intracellular proteins called β-arrestins, more specifically arrestin beta 2.[104] [105] Cyclopropylmethanamine derivatives such as (−)-19 have also been shown to act as 5-HT2A/2C agonists with functional selectivity for Gq-mediated signaling compared with β-arrestin recruitment.[106]

Genetics

The 5-HT2A receptors is coded by the HTR2A gene.In humans the gene is located on chromosome 13.The gene has previously been called just HTR2 until the description of two related genes HTR2B and HTR2C.Several interesting polymorphisms have been identified for HTR2A:A-1438G (rs6311),C102T (rs6313) andHis452Tyr (rs6314).Many more polymorphisms exist for the gene.A 2006 paper listed 255.[107] [59]

Probable role in fibromyalgia as the T102C polymorphisms of the gene 5HT2A were common in fibromyalgia patients.[108]

Human HTR2A gene is thought to consist of 3 introns and 4 exons and to overlap with human gene HTR2A-AS1 which consists of 18 exons.[109] There are over 200 organisms that have orthologs with the human HTR2A. Currently, the best documented orthologs for HTR2A gene are the mouse,[110] and zebrafish.[111] There are 8 paralogs for the HTR2A gene. The HTR2A gene is known to interact and activate G-protein genes such as GNA14, GNAI1, GNAI3, GNAQ, and GNAZ.[112] These interactions are critical for cell signaling[113] [114] and homeostasis [115] in many organisms.[116]

In human brain tissue, regulation of HTR2A varies depending on the region: frontal cortex, amygdala, thalamus, brain stem and cerebellum. In a paper from 2016, they found that HTR2A undergoes a variety of different splicing events, including utilization of alternative splice acceptor sites, exon skipping, rare exon usage, and intron retention.

Mechanisms of regulation

There are a few mechanisms of regulation for HTR2A gene such regulated by DNA methylation at particular transcript binding sites.[117] [118] Another mechanism for the correct regulation of gene expression is achieved through alternative splicing. This is a co-transcriptional process, which allows the generation of multiple forms of mRNA transcript from a single coding unit and is emerging as an important control point for gene expression. In this process, exons or introns can be either included or excluded from precursor-mRNA resulting in multiple mature mRNA variants.[119] These mRNA variants result in different isoforms which may have antagonistic functions or differential expression patterns, yielding plasticity and adaptability to the cells.[120] One study found that the common genetic variant rs6311 regulates expression of HTR2A transcripts containing the extended 5' UTR.

Associations with psychiatric disorders

Several studies have seen links between the -1438G/A polymorphism and mood disorders, such as major depressive disorder.[121] and a strong link with an odds ratio of 1.3 has been found between the T102C polymorphism and schizophrenia.[122] This polymorphism has also been studied in relation to suicide attempts, with a study finding excess of the G/G and G/A genotypes among the suicide attempters.[123] A number of other studies were devoted to finding an association of the gene with schizophrenia, with diverging results.[124]

These individual studies may, however, not give a full picture: A review from 2007 looking at the effect of different SNPs reported in separate studies stated that "genetic association studies [of HTR2A gene variants with psychiatric disorders] report conflicting and generally negative results" with no involvement, small or a not replicated role for the genetic variant of the gene.[125]

Polymorphisms in the promoter gene coding Early growth response 3 (EGR3) are associated with schizophrenia. Studies have demonstrated a relationship between EGR3 and HTR2A, and schizophrenia-like behaviors in transgenic animals.[126] [127] Exactly how these results translate over to further biopsychological understanding of schizophrenia is still widely debated.[128] [129] There is some evidence that dysfunction of HTR2A can impact pharmacological interventions.[130]

Several studies have assessed a relationship between 5-hydroxytryptamine (serotonin) 2A receptor (5-HTR2A) gene polymorphisms with an increased risk of suicidal behavior. One study revealed that T102C polymorphism is associated with suicidal behavior [131] but other studies failed to replicate these findings and found no association between polymorphism and suicidal behavior.[132]

Treatment response

Genetics seems also to be associated to some extent with the amount of adverse events in treatment of major depression disorder.[133]

Associations with substance abuse

Polymorphisms in the 5-HT2A receptor coding gene HTR2A (rs6313 and s6311) have been shown to have conflicting associations with alcohol misuse. For example, A polymorphism in the 5-HT2A receptor coding gene HTR2A (rs6313) was reported to predict lower positive alcohol expectancy, higher refusal self-efficacy, and lower alcohol misuse in a sample of 120 young adults. However, this polymorphism did not moderate the linkages between impulsivity, cognition, and alcohol misuse.[134] There are conflicting results as other studies have found associations between T102C polymorphisms alcohol misuse.[135] [136]

Drug impact on gene expression

There is some evidence that methylation patterns may contribute to relapse behaviors in people who use stimulants.[137] In mice, psychotropic drugs such as DOI, LSD, DOM, and DOB which produced differing transcriptional patterns among several different brain regions.[127]

Methods to analyse the receptor

The receptor can be analysed by neuroimaging, radioligand, genetic analysis, measurements of ion flows, and in other ways.

Neuroimaging

The 5-HT2A receptors may be imaged with PET-scanners using the fluorine-18-altanserin,[138] MDL 100,907[139] or [<sup>11</sup>C]Cimbi-36[140] radioligands that binds to the neuroreceptor, e.g.,one study reported a reduced binding of altanserin particularly in the hippocampus in patients with major depressive disorder.[141]

Altanserin uptake decreases with age reflecting a loss of specific 5-HT2A receptors with age.[142] [143] [144]

Other

Western blot with an affinity-purified antibody and examination of 5-HT2A receptor protein samples by electrophoresis has been described. Immunohistochemical staining of 5-HT2A receptors is also possible.[2]

Further reading

External links

Notes and References

  1. Cook EH, Fletcher KE, Wainwright M, Marks N, Yan SY, Leventhal BL . Primary structure of the human platelet serotonin 5-HT2A receptor: identify with frontal cortex serotonin 5-HT2A receptor . Journal of Neurochemistry . 63 . 2 . 465–469 . August 1994 . 8035173 . 10.1046/j.1471-4159.1994.63020465.x . 40207336 .
  2. Book: Kling A . 5-HT2A: a serotonin receptor with a possible role in joint diseases . Umeå: Umeå Universitet . 2013. 978-91-7459-549-9.
  3. Book: Raote I . Ishier . Serotonin 2A (5-HT2A) Receptor Function: Ligand-Dependent Mechanisms and Pathways . Frontiers in Neuroscience . 2007 . Press/Taylor & Francis . 21204452 . 9780849339776 .
  4. Martin P, Waters N, Schmidt CJ, Carlsson A, Carlsson ML . Rodent data and general hypothesis: antipsychotic action exerted through 5-HT2A receptor antagonism is dependent on increased serotonergic tone . Journal of Neural Transmission . 105 . 4–5 . 365–396 . 1998 . 9720968 . 10.1007/s007020050064 . 20944107 .
  5. De Almeida RM, Rosa MM, Santos DM, Saft DM, Benini Q, Miczek KA . 5-HT(1B) receptors, ventral orbitofrontal cortex, and aggressive behavior in mice . Psychopharmacology . 185 . 4 . 441–450 . May 2006 . 16550387 . 10.1007/s00213-006-0333-3 . 33274637 .
  6. Eison AS, Mullins UL . Regulation of central 5-HT2A receptors: a review of in vivo studies . Behavioural Brain Research . 73 . 1–2 . 177–181 . 1996 . 8788498 . 10.1016/0166-4328(96)00092-7 . 4048975 .
  7. Yadav PN, Kroeze WK, Farrell MS, Roth BL . Antagonist functional selectivity: 5-HT2A serotonin receptor antagonists differentially regulate 5-HT2A receptor protein level in vivo . The Journal of Pharmacology and Experimental Therapeutics . 339 . 1 . 99–105 . October 2011 . 21737536 . 3186284 . 10.1124/jpet.111.183780 .
  8. Rinaldi-Carmona M, Congy C, Simiand J, Oury-Donat F, Soubrie P, Breliere JC, Le Fur G . Repeated administration of SR 46349B, a selective 5-hydroxytryptamine2 antagonist, up-regulates 5-hydroxytryptamine2 receptors in mouse brain . Molecular Pharmacology . 43 . 1 . 84–89 . January 1993 . 8423772 .
  9. Gray JA, Roth BL . Paradoxical trafficking and regulation of 5-HT(2A) receptors by agonists and antagonists . Brain Research Bulletin . 56 . 5 . 441–451 . November 2001 . 11750789 . 10.1016/s0361-9230(01)00623-2 . Bryan Roth . 271925 .
  10. Vanover KE, Davis RE . Role of 5-HT2A receptor antagonists in the treatment of insomnia . Nature and Science of Sleep . 2 . 139–150 . 28 July 2010 . 23616706 . 3630942 . 10.2147/nss.s6849 . free .
  11. Urban JD, Clarke WP, von Zastrow M, Nichols DE, Kobilka B, Weinstein H, Javitch JA, Roth BL, Christopoulos A, Sexton PM, Miller KJ, Spedding M, Mailman RB . Functional selectivity and classical concepts of quantitative pharmacology . The Journal of Pharmacology and Experimental Therapeutics . 320 . 1 . 1–13 . January 2007 . 16803859 . 10.1124/jpet.106.104463 . 447937 .
  12. Book: Sanders-Bush E, Mayer SE. Brunton LL, Lazo JS, Parker K . Goodman & Gilman's the Pharmacological Basis of Therapeutics. 11th. McGraw-Hill. New York. 2006. Chapter 11: 5-Hydroxytryptamine (Serotonin): Receptor Agonists and Antagonists. 0-07-142280-3.
  13. Book: Basic neurochemistry: molecular, cellular, and medical aspects . 1 . Siegel GJ, Albers RW . 7th . 0-12-088397-X . Academic Press . 2005 . 241.
  14. Hoyer D, Hannon JP, Martin GR . Molecular, pharmacological and functional diversity of 5-HT receptors . Pharmacology, Biochemistry, and Behavior . 71 . 4 . 533–554 . April 2002 . 11888546 . 10.1016/S0091-3057(01)00746-8 . 25543069 .
  15. Beliveau V, Ganz M, Feng L, Ozenne B, Højgaard L, Fisher PM, Svarer C, Greve DN, Knudsen GM . A High-Resolution In Vivo Atlas of the Human Brain's Serotonin System . The Journal of Neuroscience . 37 . 1 . 120–128 . January 2017 . 28053035 . 5214625 . 10.1523/JNEUROSCI.2830-16.2016 .
  16. Aghajanian GK, Marek GJ . Serotonin, via 5-HT2A receptors, increases EPSCs in layer V pyramidal cells of prefrontal cortex by an asynchronous mode of glutamate release . Brain Research . 825 . 1–2 . 161–171 . April 1999 . 10216183 . 10.1016/S0006-8993(99)01224-X . 20081913 . free .
  17. Marek GJ, Wright RA, Gewirtz JC, Schoepp DD . A major role for thalamocortical afferents in serotonergic hallucinogen receptor function in the rat neocortex . Neuroscience . 105 . 2 . 379–392 . 2001 . 11672605 . 10.1016/S0306-4522(01)00199-3 . 19764312 .
  18. Bortolozzi A, Díaz-Mataix L, Scorza MC, Celada P, Artigas F . The activation of 5-HT receptors in prefrontal cortex enhances dopaminergic activity . Journal of Neurochemistry . 95 . 6 . 1597–1607 . December 2005 . 16277612 . 10.1111/j.1471-4159.2005.03485.x . free . 18350703 . 10261/33026 .
  19. Amargós-Bosch M, Bortolozzi A, Puig MV, Serrats J, Adell A, Celada P, Toth M, Mengod G, Artigas F . Co-expression and in vivo interaction of serotonin1A and serotonin2A receptors in pyramidal neurons of prefrontal cortex . Cerebral Cortex . 14 . 3 . 281–299 . March 2004 . 14754868 . 10.1093/cercor/bhg128 . free . 10261/34683 . free .
  20. Feng J, Cai X, Zhao J, Yan Z . Serotonin receptors modulate GABA(A) receptor channels through activation of anchored protein kinase C in prefrontal cortical neurons . The Journal of Neuroscience . 21 . 17 . 6502–6511 . September 2001 . 11517239 . 6763081 . 10.1523/JNEUROSCI.21-17-06502.2001 .
  21. Marek GJ . Activation of adenosine(1) (A(1)) receptors suppresses head shakes induced by a serotonergic hallucinogen in rats . Neuropharmacology . 56 . 8 . 1082–1087 . June 2009 . 19324062 . 2706691 . 10.1016/j.neuropharm.2009.03.005 .
  22. Zhang C, Marek GJ . AMPA receptor involvement in 5-hydroxytryptamine2A receptor-mediated pre-frontal cortical excitatory synaptic currents and DOI-induced head shakes . Progress in Neuro-Psychopharmacology & Biological Psychiatry . 32 . 1 . 62–71 . January 2008 . 17728034 . 10.1016/j.pnpbp.2007.07.009 . 44889209 .
  23. Gewirtz JC, Marek GJ . Behavioral evidence for interactions between a hallucinogenic drug and group II metabotropic glutamate receptors . Neuropsychopharmacology . 23 . 5 . 569–576 . November 2000 . 11027922 . 10.1016/S0893-133X(00)00136-6 . free .
  24. Marek GJ, Zhang C . Activation of metabotropic glutamate 5 (mGlu5) receptors induces spontaneous excitatory synaptic currents in layer V pyramidal cells of the rat prefrontal cortex . Neuroscience Letters . 442 . 3 . 239–243 . September 2008 . 18621097 . 2677702 . 10.1016/j.neulet.2008.06.083 .
  25. Lambe EK, Liu RJ, Aghajanian GK . Schizophrenia, hypocretin (orexin), and the thalamocortical activating system . Schizophrenia Bulletin . 33 . 6 . 1284–1290 . November 2007 . 17656637 . 2779889 . 10.1093/schbul/sbm088 .
  26. Liu RJ, Aghajanian GK . Stress blunts serotonin- and hypocretin-evoked EPSCs in prefrontal cortex: role of corticosterone-mediated apical dendritic atrophy . Proceedings of the National Academy of Sciences of the United States of America . 105 . 1 . 359–364 . January 2008 . 18172209 . 2224217 . 10.1073/pnas.0706679105 . free . 2008PNAS..105..359L .
  27. Geurts FJ, De Schutter E, Timmermans JP . Localization of 5-HT2A, 5-HT3, 5-HT5A and 5-HT7 receptor-like immunoreactivity in the rat cerebellum . Journal of Chemical Neuroanatomy . 24 . 1 . 65–74 . June 2002 . 12084412 . 10.1016/S0891-0618(02)00020-0 . 16510169 .
  28. Maeshima T, Shutoh F, Hamada S, Senzaki K, Hamaguchi-Hamada K, Ito R, Okado N . Serotonin2A receptor-like immunoreactivity in rat cerebellar Purkinje cells . Neuroscience Letters . 252 . 1 . 72–74 . August 1998 . 9756362 . 10.1016/S0304-3940(98)00546-1 . 28549709 .
  29. Maeshima T, Shiga T, Ito R, Okado N . Expression of serotonin2A receptors in Purkinje cells of the developing rat cerebellum . Neuroscience Research . 50 . 4 . 411–417 . December 2004 . 15567478 . 10.1016/j.neures.2004.08.010 . 5772490 .
  30. Dürk T, Panther E, Müller T, Sorichter S, Ferrari D, Pizzirani C, Di Virgilio F, Myrtek D, Norgauer J, Idzko M . 5-Hydroxytryptamine modulates cytokine and chemokine production in LPS-primed human monocytes via stimulation of different 5-HTR subtypes . International Immunology . 17 . 5 . 599–606 . May 2005 . 15802305 . 10.1093/intimm/dxh242 . free .
  31. Johansen A, Holm S, Dall B, Keller S, Kristensen JL, Knudsen GM, Hansen HD . Human biodistribution and radiation dosimetry of the 5-HT2A receptor agonist Cimbi-36 labeled with carbon-11 in two positions . EJNMMI Research . 9 . 1 . 71 . July 2019 . 31367837 . 6669221 . 10.1186/s13550-019-0527-4 . free .
  32. Moreno JL, Holloway T, Albizu L, Sealfon SC, González-Maeso J . Metabotropic glutamate mGlu2 receptor is necessary for the pharmacological and behavioral effects induced by hallucinogenic 5-HT2A receptor agonists . Neuroscience Letters . 493 . 3 . 76–79 . April 2011 . 21276828 . 3064746 . 10.1016/j.neulet.2011.01.046 .
  33. Jalal B . The neuropharmacology of sleep paralysis hallucinations: serotonin 2A activation and a novel therapeutic drug . Psychopharmacology . 235 . 11 . 3083–3091 . November 2018 . 30288594 . 6208952 . 10.1007/s00213-018-5042-1 .
  34. Yu B, Becnel J, Zerfaoui M, Rohatgi R, Boulares AH, Nichols CD . Serotonin 5-hydroxytryptamine(2A) receptor activation suppresses tumor necrosis factor-alpha-induced inflammation with extraordinary potency . The Journal of Pharmacology and Experimental Therapeutics . 327 . 2 . 316–323 . November 2008 . 18708586 . 10.1124/jpet.108.143461 . 25374241 .
  35. Nau F, Yu B, Martin D, Nichols CD . Serotonin 5-HT2A receptor activation blocks TNF-α mediated inflammation in vivo . PLOS ONE . 8 . 10 . e75426 . 2013 . 24098382 . 3788795 . 10.1371/journal.pone.0075426 . free . 2013PLoSO...875426N .
  36. Van de Kar LD, Javed A, Zhang Y, Serres F, Raap DK, Gray TS . 5-HT2A receptors stimulate ACTH, corticosterone, oxytocin, renin, and prolactin release and activate hypothalamic CRF and oxytocin-expressing cells . The Journal of Neuroscience . 21 . 10 . 3572–3579 . May 2001 . 11331386 . 6762485 . 10.1523/JNEUROSCI.21-10-03572.2001 .
  37. Zhang Y, Damjanoska KJ, Carrasco GA, Dudas B, D'Souza DN, Tetzlaff J, Garcia F, Hanley NR, Scripathirathan K, Petersen BR, Gray TS, Battaglia G, Muma NA, Van de Kar LD . Evidence that 5-HT2A receptors in the hypothalamic paraventricular nucleus mediate neuroendocrine responses to (−)DOI . The Journal of Neuroscience . 22 . 21 . 9635–9642 . November 2002 . 12417689 . 6758011 . 10.1523/JNEUROSCI.22-21-09635.2002 .
  38. Harvey JA . Role of the serotonin 5-HT(2A) receptor in learning . Learning & Memory . 10 . 5 . 355–362 . 2003 . 14557608 . 218001 . 10.1101/lm.60803 .
  39. Williams GV, Rao SG, Goldman-Rakic PS, Foresta M, Ropolo M, Degan P, Pettinati I, Kow YW, Damonte G, Poggi A, Frosina G . Defective repair of 5-hydroxy-2'-deoxycytidine in Cockayne syndrome cells and its complementation by Escherichia coli formamidopyrimidine DNA glycosylase and endonuclease III . Free Radical Biology & Medicine . 48 . 5 . 681–690 . March 2010 . 11923449 . 20026203-->,10.1016/j.freeradbiomed.2009.12.007 . 6758292 .
  40. Passier A, van Puijenbroek E . Mirtazapine-induced arthralgia . British Journal of Clinical Pharmacology . 60 . 5 . 570–572 . November 2005 . 16236049 . 1884949 . 10.1111/j.1365-2125.2005.02481.x .
  41. Adwan MH . An update on drug-induced arthritis . Rheumatology International . 36 . 8 . 1089–1097 . August 2016 . 27000044 . 10.1007/s00296-016-3462-y . 25401280 .
  42. Herth MM, Knudsen GM . Current radiosynthesis strategies for 5-HT2A receptor PET tracers . Journal of Labelled Compounds & Radiopharmaceuticals . 58 . 7 . 265–273 . June 2015 . 25997728 . 10.1002/jlcr.3288 .
  43. Web site: Beer R . 2023-06-13 . Anblick von toten Fliegen lässt Fliegen altern . 2023-06-14 . science.ORF.at . de.
  44. Gendron CM, Chakraborty TS, Duran C, Dono T, Pletcher SD . Ring neurons in the Drosophila central complex act as a rheostat for sensory modulation of aging . PLOS Biology . 21 . 6 . e3002149 . June 2023 . 37310911 . 10.1371/journal.pbio.3002149 . 10263353 . free .
  45. Nichols DE . Hallucinogens . Pharmacology & Therapeutics . 101 . 2 . 131–181 . February 2004 . 14761703 . 10.1016/j.pharmthera.2003.11.002 .
  46. Blaazer AR, Smid P, Kruse CG . Structure-activity relationships of phenylalkylamines as agonist ligands for 5-HT(2A) receptors . ChemMedChem . 3 . 9 . 1299–1309 . September 2008 . 18666267 . 10.1002/cmdc.200800133 . 7537908 .
  47. Moreno JL, Muguruza C, Umali A, Mortillo S, Holloway T, Pilar-Cuéllar F, Mocci G, Seto J, Callado LF, Neve RL, Milligan G, Sealfon SC, López-Giménez JF, Meana JJ, Benson DL, González-Maeso J . Identification of three residues essential for 5-hydroxytryptamine 2A-metabotropic glutamate 2 (5-HT2A·mGlu2) receptor heteromerization and its psychoactive behavioral function . The Journal of Biological Chemistry . 287 . 53 . 44301–44319 . December 2012 . 23129762 . 3531745 . 10.1074/jbc.M112.413161 . free .
  48. González-Maeso J, Ang RL, Yuen T, Chan P, Weisstaub NV, López-Giménez JF, Zhou M, Okawa Y, Callado LF, Milligan G, Gingrich JA, Filizola M, Meana JJ, Sealfon SC . Identification of a serotonin/glutamate receptor complex implicated in psychosis . Nature . 452 . 7183 . 93–97 . March 2008 . 18297054 . 2743172 . 10.1038/nature06612 . 2008Natur.452...93G .
  49. Taddeucci A, Olivero G, Roggeri A, Milanese C, Giorgio FP, Grilli M, Marchi M, Garrone B, Pittaluga A . Presynaptic 5-HT2A-mGlu2/3 Receptor-Receptor Crosstalk in the Prefrontal Cortex: Metamodulation of Glutamate Exocytosis . Cells . 11 . 19 . 3035 . September 2022 . 36230998 . 9562019 . 10.3390/cells11193035 . free .
  50. Wingen M, Kuypers KP, Ramaekers JG . The role of 5-HT1a and 5-HT2A receptors in attention and motor control: a mechanistic study in healthy volunteers . Psychopharmacology . 190 . 3 . 391–400 . February 2007 . 17124621 . 10.1007/s00213-006-0614-x . 25125461 .
  51. Wingen M, Kuypers KP, Ramaekers JG . Selective verbal and spatial memory impairment after 5-HT1A and 5-HT2A receptor blockade in healthy volunteers pre-treated with an SSRI . Journal of Psychopharmacology . 21 . 5 . 477–485 . July 2007 . 17092965 . 10.1177/0269881106072506 . 19575488 .
  52. Braden MR, Parrish JC, Naylor JC, Nichols DE . Molecular interaction of serotonin 5-HT2A receptor residues Phe339(6.51) and Phe340(6.52) with superpotent N-benzyl phenethylamine agonists . Molecular Pharmacology . 70 . 6 . 1956–1964 . December 2006 . 17000863 . 10.1124/mol.106.028720 . 15840304 .
  53. Prabhakaran J, Solingapuram Sai KK, Zanderigo F, Rubin-Falcone H, Jorgensen MJ, Kaplan JR, Tooke KI, Mintz A, Mann JJ, Kumar JS . In vivo evaluation of [<sup>18</sup>F]FECIMBI-36, an agonist 5-HT2A/2C receptor PET radioligand in nonhuman primate . Bioorganic & Medicinal Chemistry Letters . 27 . 1 . 21–23 . January 2017 . 27889455 . 5348621 . 10.1016/j.bmcl.2016.11.043 .
  54. McLean TH, Parrish JC, Braden MR, Marona-Lewicka D, Gallardo-Godoy A, Nichols DE . 1-Aminomethylbenzocycloalkanes: conformationally restricted hallucinogenic phenethylamine analogues as functionally selective 5-HT2A receptor agonists . Journal of Medicinal Chemistry . 49 . 19 . 5794–5803 . September 2006 . 16970404 . 10.1021/jm060656o .
  55. Ennis MD, Hoffman RL, Ghazal NB, Olson RM, Knauer CS, Chio CL, Hyslop DK, Campbell JE, Fitzgerald LW, Nichols NF, Svensson KA, McCall RB, Haber CL, Kagey ML, Dinh DM . 2,3,4,5-tetrahydro- and 2,3,4,5,11,11a-hexahydro-1H-[1,4]diazepino[1,7-a]indoles: new templates for 5-HT(2C) agonists . Bioorganic & Medicinal Chemistry Letters . 13 . 14 . 2369–2372 . July 2003 . 12824036 . 10.1016/S0960-894X(03)00403-7 .
  56. Ettrup A, da Cunha-Bang S, McMahon B, Lehel S, Dyssegaard A, Skibsted AW, Jørgensen LM, Hansen M, Baandrup AO, Bache S, Svarer C, Kristensen JL, Gillings N, Madsen J, Knudsen GM . Serotonin 2A receptor agonist binding in the human brain with [¹¹C]Cimbi-36 . Journal of Cerebral Blood Flow and Metabolism . 34 . 7 . 1188–1196 . July 2014 . 24780897 . 4083382 . 10.1038/jcbfm.2014.68 .
  57. Web site: Design and Synthesis of Selective Serotonin Receptor Agonists for Positron Emission Tomography Imaging of the Brain (Revised, Duplex print).pdf. Google Docs.
  58. Dong C, Ly C, Dunlap LE, Vargas MV, Sun J, Hwang IW, Azinfar A, Oh WC, Wetsel WC, Olson DE, Tian L . Psychedelic-inspired drug discovery using an engineered biosensor . Cell . 184 . 10 . 2779–2792.e18 . May 2021 . 33915107 . 8122087 . 10.1016/j.cell.2021.03.043 . free .
  59. Chambers JJ, Kurrasch-Orbaugh DM, Parker MA, Nichols DE . Enantiospecific synthesis and pharmacological evaluation of a series of super-potent, conformationally restricted 5-HT(2A/2C) receptor agonists . Journal of Medicinal Chemistry . 44 . 6 . 1003–1010 . March 2001 . 11300881 . 10.1021/jm000491y .
  60. Canal CE, Morgan D . Head-twitch response in rodents induced by the hallucinogen 2,5-dimethoxy-4-iodoamphetamine: a comprehensive history, a re-evaluation of mechanisms, and its utility as a model . Drug Testing and Analysis . 4 . 7–8 . 556–576 . July 2012 . 22517680 . 3722587 . 10.1002/dta.1333 .
  61. Gatch MB, Kozlenkov A, Huang RQ, Yang W, Nguyen JD, González-Maeso J, Rice KC, France CP, Dillon GH, Forster MJ, Schetz JA . The HIV antiretroviral drug efavirenz has LSD-like properties . Neuropsychopharmacology . 38 . 12 . 2373–2384 . November 2013 . 23702798 . 3799056 . 10.1038/npp.2013.135 .
  62. Juncosa JI, Hansen M, Bonner LA, Cueva JP, Maglathlin R, McCorvy JD, Marona-Lewicka D, Lill MA, Nichols DE . Extensive rigid analogue design maps the binding conformation of potent N-benzylphenethylamine 5-HT2A serotonin receptor agonist ligands . ACS Chemical Neuroscience . 4 . 1 . 96–109 . January 2013 . 23336049 . 3547484 . 10.1021/cn3000668 .
  63. Egan CT, Herrick-Davis K, Miller K, Glennon RA, Teitler M . Agonist activity of LSD and lisuride at cloned 5HT2A and 5HT2C receptors . Psychopharmacology . 136 . 4 . 409–414 . April 1998 . 9600588 . 10.1007/s002130050585 . 3021798 .
  64. Hofmann C, Penner U, Dorow R, Pertz HH, Jähnichen S, Horowski R, Latté KP, Palla D, Schurad B . Lisuride, a dopamine receptor agonist with 5-HT2B receptor antagonist properties: absence of cardiac valvulopathy adverse drug reaction reports supports the concept of a crucial role for 5-HT2B receptor agonism in cardiac valvular fibrosis . Clinical Neuropharmacology . 29 . 2 . 80–86 . 2006 . 16614540 . 10.1097/00002826-200603000-00005 . 33849447 .
  65. Janowsky A, Eshleman AJ, Johnson RA, Wolfrum KM, Hinrichs DJ, Yang J, Zabriskie TM, Smilkstein MJ, Riscoe MK . Mefloquine and psychotomimetics share neurotransmitter receptor and transporter interactions in vitro . Psychopharmacology . 231 . 14 . 2771–2783 . July 2014 . 24488404 . 4097020 . 10.1007/s00213-014-3446-0 .
  66. de la Fuente Revenga M, Shah UH, Nassehi N, Jaster AM, Hemanth P, Sierra S, Dukat M, González-Maeso J . Psychedelic-like Properties of Quipazine and Its Structural Analogues in Mice . ACS Chemical Neuroscience . 12 . 5 . 831–844 . March 2021 . 33400504 . 7933111 . 10.1021/acschemneuro.0c00291 .
  67. Åstrand A, Guerrieri D, Vikingsson S, Kronstrand R, Green H . In vitro characterization of new psychoactive substances at the μ-opioid, CB1, 5HT1A, and 5-HT2A receptors-On-target receptor potency and efficacy, and off-target effects . Forensic Science International . 317 . 110553 . December 2020 . 33160102 . 10.1016/j.forsciint.2020.110553 . free .
  68. Ennis MD, Hoffman RL, Ghazal NB, Olson RM, Knauer CS, Chio CL, Hyslop DK, Campbell JE, Fitzgerald LW, Nichols NF, Svensson KA, McCall RB, Haber CL, Kagey ML, Dinh DM . 2,3,4,5-tetrahydro- and 2,3,4,5,11,11a-hexahydro-1H-[1,4]diazepino[1,7-a]indoles: new templates for 5-HT(2C) agonists . Bioorganic & Medicinal Chemistry Letters . 13 . 14 . 2369–2372 . July 2003 . 12824036 . 10.1016/s0960-894x(03)00403-7 .
  69. Smith BM, Smith JM, Tsai JH, Schultz JA, Gilson CA, Estrada SA, Chen RR, Park DM, Prieto EB, Gallardo CS, Sengupta D, Thomsen WJ, Saldana HR, Whelan KT, Menzaghi F, Webb RR, Beeley NR . Discovery and SAR of new benzazepines as potent and selective 5-HT(2C) receptor agonists for the treatment of obesity . Bioorganic & Medicinal Chemistry Letters . 15 . 5 . 1467–1470 . March 2005 . 15713408 . 10.1016/j.bmcl.2004.12.080 .
  70. WO . WO2007149728 . Aryl and heteroaryl tetrahydrobenzazepine derivatives and their use for treating glaucoma . Mohapatra S, Hellberg MR, Feng Z . Alcon Manufacturing, Ltd. .
  71. Smith BM, Smith JM, Tsai JH, Schultz JA, Gilson CA, Estrada SA, Chen RR, Park DM, Prieto EB, Gallardo CS, Sengupta D, Dosa PI, Covel JA, Ren A, Webb RR, Beeley NR, Martin M, Morgan M, Espitia S, Saldana HR, Bjenning C, Whelan KT, Grottick AJ, Menzaghi F, Thomsen WJ . Discovery and structure-activity relationship of (1R)-8-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine (Lorcaserin), a selective serotonin 5-HT2C receptor agonist for the treatment of obesity . Journal of Medicinal Chemistry . 51 . 2 . 305–313 . January 2008 . 18095642 . 10.1021/jm0709034 .
  72. Jensen AA, Plath N, Pedersen MH, Isberg V, Krall J, Wellendorph P, Stensbøl TB, Gloriam DE, Krogsgaard-Larsen P, Frølund B . Design, synthesis, and pharmacological characterization of N- and O-substituted 5,6,7,8-tetrahydro-4H-isoxazolo[4,5-d]azepin-3-ol analogues: novel 5-HT(2A)/5-HT(2C) receptor agonists with pro-cognitive properties . Journal of Medicinal Chemistry . 56 . 3 . 1211–1227 . February 2013 . 23301527 . 10.1021/jm301656h .
  73. Cao D, Yu J, Wang H, Luo Z, Liu X, He L, Qi J, Fan L, Tang L, Chen Z, Li J, Cheng J, Wang S . Structure-based discovery of nonhallucinogenic psychedelic analogs . Science . 375 . 6579 . 403–411 . January 2022 . 35084960 . 10.1126/science.abl8615 . 246360313 . 2022Sci...375..403C .
  74. Kaplan AL, Confair DN, Kim K, Barros-Álvarez X, Rodriguiz RM, Yang Y, Kweon OS, Che T, McCorvy JD, Kamber DN, Phelan JP, Martins LC, Pogorelov VM, DiBerto JF, Slocum ST, Huang XP, Kumar JM, Robertson MJ, Panova O, Seven AB, Wetsel AQ, Wetsel WC, Irwin JJ, Skiniotis G, Shoichet BK, Roth BL, Ellman JA . Bespoke library docking for 5-HT2A receptor agonists with antidepressant activity . Nature . 610 . 7932 . 582–591 . October 2022 . 36171289 . 10.1038/s41586-022-05258-z . 9996387 . 2022Natur.610..582K . 252598838 .
  75. Lyu J, Kapolka N, Gumpper R, Alon A, Wang L, Jain MK, Barros-Álvarez X, Sakamoto K, Kim Y, DiBerto J, Kim K, Tummino TA, Huang S, Irwin JJ, Tarkhanova OO, Moroz Y, Skiniotis G, Kruse AC, Shoichet BK, Roth BL . AlphaFold2 structures template ligand discovery . bioRxiv . December 2023 . 38187536 . 10769324 . 10.1101/2023.12.20.572662 .
  76. Orr MJ, Cao AB, Wang CT, Gaisin A, Csakai A, Friswold AP, Meltzer HY, McCorvy JD, Scheidt KA . Discovery of Highly Potent Serotonin 5-HT2 Receptor Agonists Inspired by Heteroyohimbine Natural Products . ACS Medicinal Chemistry Letters . 13 . 4 . 648–657 . April 2022 . 35450369 . 9014500 . 10.1021/acsmedchemlett.1c00694 .
  77. Sharif NA, McLaughlin MA, Kelly CR . AL-34662: a potent, selective, and efficacious ocular hypotensive serotonin-2 receptor agonist . Journal of Ocular Pharmacology and Therapeutics . 23 . 1 . 1–13 . February 2007 . 17341144 . 10.1089/jop.2006.0093 .
  78. May JA, Dantanarayana AP, Zinke PW, McLaughlin MA, Sharif NA . 1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity . Journal of Medicinal Chemistry . 49 . 1 . 318–328 . January 2006 . 16392816 . 10.1021/jm050663x .
  79. Marek GJ, Martin-Ruiz R, Abo A, Artigas F . The selective 5-HT2A receptor antagonist M100907 enhances antidepressant-like behavioral effects of the SSRI fluoxetine . Neuropsychopharmacology . 30 . 12 . 2205–2215 . December 2005 . 15886717 . 10.1038/sj.npp.1300762 . free .
  80. Ishima T, Futamura T, Ohgi Y, Yoshimi N, Kikuchi T, Hashimoto K . Potentiation of neurite outgrowth by brexpiprazole, a novel serotonin-dopamine activity modulator: a role for serotonin 5-HT1A and 5-HT2A receptors . European Neuropsychopharmacology . 25 . 4 . 505–511 . April 2015 . 25687838 . 10.1016/j.euroneuro.2015.01.014 . free .
  81. Das S, Barnwal P, Winston AB, Mondal S, Saha I . Brexpiprazole: so far so good . Therapeutic Advances in Psychopharmacology . 6 . 1 . 39–54 . February 2016 . 26913177 . 4749739 . 10.1177/2045125315614739 .
  82. Pälvimäki EP, Roth BL, Majasuo H, Laakso A, Kuoppamäki M, Syvälahti E, Hietala J . Interactions of selective serotonin reuptake inhibitors with the serotonin 5-HT2c receptor . Psychopharmacology . 126 . 3 . 234–240 . August 1996 . 8876023 . 10.1007/bf02246453 . 24889381 .
  83. Book: Rang HP. Pharmacology. Churchill Livingstone. Edinburgh. 2003. 0-443-07145-4. Page 187
  84. Shireman BT, Dvorak CA, Rudolph DA, Bonaventure P, Nepomuceno D, Dvorak L, Miller KL, Lovenberg TW, Carruthers NI . 2-Alkyl-4-aryl-pyrimidine fused heterocycles as selective 5-HT2A antagonists . Bioorganic & Medicinal Chemistry Letters . 18 . 6 . 2103–2108 . March 2008 . 18282705 . 10.1016/j.bmcl.2008.01.090 .
  85. Westkaemper RB, Runyon SP, Bondarev ML, Savage JE, Roth BL, Glennon RA . 9-(Aminomethyl)-9,10-dihydroanthracene is a novel and unlikely 5-HT2A receptor antagonist . European Journal of Pharmacology . 380 . 1 . R5–R7 . September 1999 . 10513561 . 10.1016/S0014-2999(99)00525-7 .
  86. Westkaemper RB, Glennon RA . Application of ligand SAR, receptor modeling and receptor mutagenesis to the discovery and development of a new class of 5-HT(2A) ligands . Current Topics in Medicinal Chemistry . 2 . 6 . 575–598 . June 2002 . 12052195 . 10.2174/1568026023393741 . 23576058 .
  87. Peddi S, Roth BL, Glennon RA, Westkaemper RB . Spiro[9,10-dihydroanthracene]-9,3'-pyrrolidine-a structurally unique tetracyclic 5-HT2A receptor antagonist . European Journal of Pharmacology . 482 . 1–3 . 335–337 . December 2003 . 14660041 . 10.1016/j.ejphar.2003.09.059 .
  88. Runyon SP, Mosier PD, Roth BL, Glennon RA, Westkaemper RB . Potential modes of interaction of 9-aminomethyl-9,10-dihydroanthracene (AMDA) derivatives with the 5-HT2A receptor: a ligand structure-affinity relationship, receptor mutagenesis and receptor modeling investigation . Journal of Medicinal Chemistry . 51 . 21 . 6808–6828 . November 2008 . 18847250 . 3088499 . 10.1021/jm800771x .
  89. Wilson KJ, van Niel MB, Cooper L, Bloomfield D, O'Connor D, Fish LR, MacLeod AM . 2,5-Disubstituted pyridines: the discovery of a novel series of 5-HT2A ligands . Bioorganic & Medicinal Chemistry Letters . 17 . 9 . 2643–2648 . May 2007 . 17314044 . 10.1016/j.bmcl.2007.01.098 .
  90. Marcinkowska M, Kubacka M, Zagorska A, Jaromin A, Fajkis-Zajaczkowska N, Kolaczkowski M . Exploring the antiplatelet activity of serotonin 5-HT2A receptor antagonists bearing 6-fluorobenzo[d]isoxazol-3-yl)propyl) motif- as potential therapeutic agents in the prevention of cardiovascular diseases . Biomedicine & Pharmacotherapy . 145 . 112424 . January 2022 . 34785417 . 10.1016/j.biopha.2021.112424 . 244111116 . free .
  91. Nilsson T, Longmore J, Shaw D, Pantev E, Bard JA, Branchek T, Edvinsson L . Characterisation of 5-HT receptors in human coronary arteries by molecular and pharmacological techniques . European Journal of Pharmacology . 372 . 1 . 49–56 . May 1999 . 10374714 . 10.1016/S0014-2999(99)00114-4 .
  92. Nagatomo T, Rashid M, Abul Muntasir H, Komiyama T . Functions of 5-HT2A receptor and its antagonists in the cardiovascular system . Pharmacology & Therapeutics . 104 . 1 . 59–81 . October 2004 . 15500909 . 10.1016/j.pharmthera.2004.08.005 .
  93. Weiner DM, Burstein ES, Nash N, Croston GE, Currier EA, Vanover KE, Harvey SC, Donohue E, Hansen HC, Andersson CM, Spalding TA, Gibson DF, Krebs-Thomson K, Powell SB, Geyer MA, Hacksell U, Brann MR . 5-hydroxytryptamine2A receptor inverse agonists as antipsychotics . The Journal of Pharmacology and Experimental Therapeutics . 299 . 1 . 268–276 . October 2001 . 11561089 .
  94. Vanover KE, Harvey SC, Son T, Bradley SR, Kold H, Makhay M, Veinbergs I, Spalding TA, Weiner DM, Andersson CM, Tolf BR, Brann MR, Hacksell U, Davis RE . Pharmacological characterization of AC-90179 [2-(4-methoxyphenyl)-N-(4-methyl-benzyl)-N-(1-methyl-piperidin-4-yl)-acetamide hydrochloride]: a selective serotonin 2A receptor inverse agonist . The Journal of Pharmacology and Experimental Therapeutics . 310 . 3 . 943–951 . September 2004 . 15102927 . 10.1124/jpet.104.066688 . 12205122 .
  95. Rosenberg R, Seiden DJ, Hull SG, Erman M, Schwartz H, Anderson C, Prosser W, Shanahan W, Sanchez M, Chuang E, Roth T . APD125, a selective serotonin 5-HT(2A) receptor inverse agonist, significantly improves sleep maintenance in primary insomnia . Sleep . 31 . 12 . 1663–1671 . December 2008 . 19090322 . 2603489 . 10.1093/sleep/31.12.1663 .
  96. Vanover KE, Weiner DM, Makhay M, Veinbergs I, Gardell LR, Lameh J, Del Tredici AL, Piu F, Schiffer HH, Ott TR, Burstein ES, Uldam AK, Thygesen MB, Schlienger N, Andersson CM, Son TY, Harvey SC, Powell SB, Geyer MA, Tolf BR, Brann MR, Davis RE . Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine(2A) receptor inverse agonist . The Journal of Pharmacology and Experimental Therapeutics . 317 . 2 . 910–918 . May 2006 . 16469866 . 10.1124/jpet.105.097006 . 22681576 .
  97. Gardell LR, Vanover KE, Pounds L, Johnson RW, Barido R, Anderson GT, Veinbergs I, Dyssegaard A, Brunmark P, Tabatabaei A, Davis RE, Brann MR, Hacksell U, Bonhaus DW . ACP-103, a 5-hydroxytryptamine 2A receptor inverse agonist, improves the antipsychotic efficacy and side-effect profile of haloperidol and risperidone in experimental models . The Journal of Pharmacology and Experimental Therapeutics . 322 . 2 . 862–870 . August 2007 . 17519387 . 10.1124/jpet.107.121715 . 28861527 .
  98. Vanover KE, Betz AJ, Weber SM, Bibbiani F, Kielaite A, Weiner DM, Davis RE, Chase TN, Salamone JD . A 5-HT2A receptor inverse agonist, ACP-103, reduces tremor in a rat model and levodopa-induced dyskinesias in a monkey model . Pharmacology, Biochemistry, and Behavior . 90 . 4 . 540–544 . October 2008 . 18534670 . 2806670 . 10.1016/j.pbb.2008.04.010 .
  99. Abbas A, Roth BL . Pimavanserin tartrate: a 5-HT2A inverse agonist with potential for treating various neuropsychiatric disorders . Expert Opinion on Pharmacotherapy . 9 . 18 . 3251–3259 . December 2008 . 19040345 . 10.1517/14656560802532707 . 71240383 .
  100. Web site: FDA approves first drug to treat hallucinations and delusions associated with Parkinson's disease. Office of the Commissioner . 10 September 2019. FDA.
  101. Moya PR, Berg KA, Gutiérrez-Hernandez MA, Sáez-Briones P, Reyes-Parada M, Cassels BK, Clarke WP . Functional selectivity of hallucinogenic phenethylamine and phenylisopropylamine derivatives at human 5-hydroxytryptamine (5-HT)2A and 5-HT2C receptors . The Journal of Pharmacology and Experimental Therapeutics . 321 . 3 . 1054–1061 . June 2007 . 17337633 . 10.1124/jpet.106.117507 . 11651502 .
  102. González-Maeso J, Weisstaub NV, Zhou M, Chan P, Ivic L, Ang R, Lira A, Bradley-Moore M, Ge Y, Zhou Q, Sealfon SC, Gingrich JA . Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior . Neuron . 53 . 3 . 439–452 . February 2007 . 17270739 . 10.1016/j.neuron.2007.01.008 . 16309730 . free .
  103. Cussac D, Boutet-Robinet E, Ailhaud MC, Newman-Tancredi A, Martel JC, Danty N, Rauly-Lestienne I . Agonist-directed trafficking of signalling at serotonin 5-HT2A, 5-HT2B and 5-HT2C-VSV receptors mediated Gq/11 activation and calcium mobilisation in CHO cells . European Journal of Pharmacology . 594 . 1–3 . 32–38 . October 2008 . 18703043 . 10.1016/j.ejphar.2008.07.040 .
  104. Schmid CL, Raehal KM, Bohn LM . Agonist-directed signaling of the serotonin 2A receptor depends on beta-arrestin-2 interactions in vivo . Proceedings of the National Academy of Sciences of the United States of America . 105 . 3 . 1079–1084 . January 2008 . 18195357 . 2242710 . 10.1073/pnas.0708862105 . free .
  105. Abbas A, Roth BL . Arresting serotonin . Proceedings of the National Academy of Sciences of the United States of America . 105 . 3 . 831–832 . January 2008 . 18195368 . 2242676 . 10.1073/pnas.0711335105 . free . 2008PNAS..105..831A .
  106. Zhang G, Cheng J, McCorvy JD, Lorello PJ, Caldarone BJ, Roth BL, Kozikowski AP . Discovery of N-Substituted (2-Phenylcyclopropyl)methylamines as Functionally Selective Serotonin 2C Receptor Agonists for Potential Use as Antipsychotic Medications . Journal of Medicinal Chemistry . 60 . 14 . 6273–6288 . July 2017 . 28657744 . 7374938 . 10.1021/acs.jmedchem.7b00584 .
  107. Bonis J, Furlong LI, Sanz F . OSIRIS: a tool for retrieving literature about sequence variants . Bioinformatics . 22 . 20 . 2567–2569 . October 2006 . 16882651 . 10.1093/bioinformatics/btl421 . Supplementary material to article . free .
  108. Book: Female Sexual Pain Disorders: Evaluation and Management. Goldstein AT, Pukall C, Goldstein IL. Wiley. 2020. 978-1119482666. 2. Fibromyalgia and Female Sexual Pain Disorders.
  109. Ruble CL, Smith RM, Calley J, Munsie L, Airey DC, Gao Y, Shin JH, Hyde TM, Straub RE, Weinberger DR, Nisenbaum LK . Genomic structure and expression of the human serotonin 2A receptor gene (HTR2A) locus: identification of novel HTR2A and antisense (HTR2A-AS1) exons . BMC Genetics . 17 . 1 . 16 . January 2016 . 26738766 . 4702415 . 10.1186/s12863-015-0325-6 . free .
  110. Medrihan L, Sagi Y, Inde Z, Krupa O, Daniels C, Peyrache A, Greengard P . Initiation of Behavioral Response to Antidepressants by Cholecystokinin Neurons of the Dentate Gyrus . Neuron . 95 . 3 . 564–576.e4 . August 2017 . 28735749 . 10.1016/j.neuron.2017.06.044 . free .
  111. Griffin A, Hamling KR, Knupp K, Hong S, Lee LP, Baraban SC . Clemizole and modulators of serotonin signalling suppress seizures in Dravet syndrome . Brain . 140 . 3 . 669–683 . March 2017 . 28073790 . 6075536 . 10.1093/brain/aww342 .
  112. Giulietti M, Vivenzio V, Piva F, Principato G, Bellantuono C, Nardi B . How much do we know about the coupling of G-proteins to serotonin receptors? . Molecular Brain . 7 . 1 . 49 . July 2014 . 25011628 . 4105882 . 10.1186/s13041-014-0049-y . free .
  113. Lal D, May P, Perez-Palma E, Samocha KE, Kosmicki JA, Robinson EB, Møller RS, Krause R, Nürnberg P, Weckhuysen S, De Jonghe P, Guerrini R, Niestroj LM, Du J, Marini C, Ware JS, Kurki M, Gormley P, Tang S, Wu S, Biskup S, Poduri A, Neubauer BA, Koeleman BP, Helbig KL, Weber YG, Helbig I, Majithia AR, Palotie A, Daly MJ . Gene family information facilitates variant interpretation and identification of disease-associated genes in neurodevelopmental disorders . Genome Medicine . 12 . 1 . 28 . March 2020 . 32183904 . 7079346 . 10.1186/s13073-020-00725-6 . free .
  114. Gao W, Guo N, Zhao S, Chen Z, Zhang W, Yan F, Liao H, Chi K . HTR2A promotes the development of cardiac hypertrophy by activating PI3K-PDK1-AKT-mTOR signaling . Cell Stress & Chaperones . 25 . 6 . 899–908 . November 2020 . 32519137 . 7591670 . 10.1007/s12192-020-01124-x .
  115. Cao X, Wang Y, Shu D, Qu H, Luo C, Hu X . Food intake-related genes in chicken determined through combinatorial genome-wide association study and transcriptome analysis . Animal Genetics . 51 . 5 . 741–751 . October 2020 . 32720725 . 10.1111/age.12980 . 220839883 .
  116. Garza-Brenner E, Sifuentes-Rincón AM, Randel RD, Paredes-Sánchez FA, Parra-Bracamonte GM, Arellano Vera W, Rodríguez Almeida FA, Segura Cabrera A . Association of SNPs in dopamine and serotonin pathway genes and their interacting genes with temperament traits in Charolais cows . Journal of Applied Genetics . 58 . 3 . 363–371 . August 2017 . 27987181 . 10.1007/s13353-016-0383-0 . 34463383 .
  117. Cheah SY, Lawford BR, Young RM, Morris CP, Voisey J . mRNA Expression and DNA Methylation Analysis of Serotonin Receptor 2A (HTR2A) in the Human Schizophrenic Brain . Genes . 8 . 1 . 14 . January 2017 . 28054990 . 5295009 . 10.3390/genes8010014 . free .
  118. Falkenberg VR, Gurbaxani BM, Unger ER, Rajeevan MS . Functional genomics of serotonin receptor 2A (HTR2A): interaction of polymorphism, methylation, expression and disease association . Neuromolecular Medicine . 13 . 1 . 66–76 . March 2011 . 20941551 . 3044825 . 10.1007/s12017-010-8138-2 .
  119. Kelemen O, Convertini P, Zhang Z, Wen Y, Shen M, Falaleeva M, Stamm S . Function of alternative splicing . Gene . 514 . 1 . 1–30 . February 2013 . 22909801 . 5632952 . 10.1016/j.gene.2012.07.083 .
  120. Wang ET, Ward AJ, Cherone JM, Giudice J, Wang TT, Treacy DJ, Lambert NJ, Freese P, Saxena T, Cooper TA, Burge CB . Antagonistic regulation of mRNA expression and splicing by CELF and MBNL proteins . Genome Research . 25 . 6 . 858–871 . June 2015 . 25883322 . 4448682 . 10.1101/gr.184390.114 .
  121. Choi MJ, Lee HJ, Lee HJ, Ham BJ, Cha JH, Ryu SH, Lee MS . Association between major depressive disorder and the -1438A/G polymorphism of the serotonin 2A receptor gene . Neuropsychobiology . 49 . 1 . 38–41 . 2004 . 14730199 . 10.1159/000075337 . 19528052 .
  122. Williams J, Spurlock G, McGuffin P, Mallet J, Nöthen MM, Gill M, Aschauer H, Nylander PO, Macciardi F, Owen MJ . Association between schizophrenia and T102C polymorphism of the 5-hydroxytryptamine type 2a-receptor gene. European Multicentre Association Study of Schizophrenia (EMASS) Group . Lancet . 347 . 9011 . 1294–1296 . May 1996 . 8622505 . 10.1016/s0140-6736(96)90939-3 . 8510590 .
  123. Vaquero-Lorenzo C, Baca-Garcia E, Diaz-Hernandez M, Perez-Rodriguez MM, Fernandez-Navarro P, Giner L, Carballo JJ, Saiz-Ruiz J, Fernandez-Piqueras J, Baldomero EB, de Leon J, Oquendo MA . Association study of two polymorphisms of the serotonin-2A receptor gene and suicide attempts . American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics . 147B . 5 . 645–649 . July 2008 . 18163387 . 10.1002/ajmg.b.30642 . 31504282 .
  124. http://www.schizophreniaforum.org/res/sczgene/geneoverview.asp?geneid=293 Gene Overview of All Published Schizophrenia-Association Studies for HTR2A
  125. Serretti A, Drago A, De Ronchi D . HTR2A gene variants and psychiatric disorders: a review of current literature and selection of SNPs for future studies . Current Medicinal Chemistry . 14 . 19 . 2053–2069 . 2007 . 17691947 . 10.2174/092986707781368450 .
  126. Maple AM, Zhao X, Elizalde DI, McBride AK, Gallitano AL . Htr2a Expression Responds Rapidly to Environmental Stimuli in an Egr3-Dependent Manner . ACS Chemical Neuroscience . 6 . 7 . 1137–1142 . July 2015 . 25857407 . 4565721 . 10.1021/acschemneuro.5b00031 .
  127. Williams AA, Ingram WM, Levine S, Resnik J, Kamel CM, Lish JR, Elizalde DI, Janowski SA, Shoker J, Kozlenkov A, González-Maeso J, Gallitano AL . Reduced levels of serotonin 2A receptors underlie resistance of Egr3-deficient mice to locomotor suppression by clozapine . Neuropsychopharmacology . 37 . 10 . 2285–2298 . September 2012 . 22692564 . 3422493 . 10.1038/npp.2012.81 .
  128. Latorre E, Mesonero JE, Harries LW . Alternative splicing in serotonergic system: Implications in neuropsychiatric disorders . Journal of Psychopharmacology . 33 . 11 . 1352–1363 . November 2019 . 31210090 . 10.1177/0269881119856546 . 190531249 .
  129. Spies M, Nasser A, Ozenne B, Jensen PS, Knudsen GM, Fisher PM . Common HTR2A variants and 5-HTTLPR are not associated with human in vivo serotonin 2A receptor levels . Human Brain Mapping . 41 . 16 . 4518–4528 . November 2020 . 32697408 . 7555071 . 10.1002/hbm.25138 .
  130. Qesseveur G, Petit AC, Nguyen HT, Dahan L, Colle R, Rotenberg S, Seif I, Robert P, David D, Guilloux JP, Gardier AM, Verstuyft C, Becquemont L, Corruble E, Guiard BP . Genetic dysfunction of serotonin 2A receptor hampers response to antidepressant drugs: A translational approach . Neuropharmacology . 105 . 142–153 . June 2016 . 26764241 . 10.1016/j.neuropharm.2015.12.022 . 15031564 .
  131. Ghasemi A, Seifi M, Baybordi F, Danaei N, Samadi Rad B . Association between serotonin 2A receptor genetic variations, stressful life events and suicide . Gene . 658 . 191–197 . June 2018 . 29526601 . 10.1016/j.gene.2018.03.023 . 4854262 .
  132. Videtic A, Pungercic G, Pajnic IZ, Zupanc T, Balazic J, Tomori M, Komel R . Association study of seven polymorphisms in four serotonin receptor genes on suicide victims . American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics . 141B . 6 . 669–672 . September 2006 . 16856120 . 10.1002/ajmg.b.30390 . 9279191 .
  133. Laje G, McMahon FJ . The pharmacogenetics of major depression: past, present, and future . Biological Psychiatry . 62 . 11 . 1205–1207 . December 2007 . 17949692 . 10.1016/j.biopsych.2007.09.016 . 37225993 .
  134. Leamy TE, Connor JP, Voisey J, Young RM, Gullo MJ . Alcohol misuse in emerging adulthood: Association of dopamine and serotonin receptor genes with impulsivity-related cognition . Addictive Behaviors . 63 . 29–36 . December 2016 . 27399274 . 10.1016/j.addbeh.2016.05.008 .
  135. Jakubczyk A, Wrzosek M, Lukaszkiewicz J, Sadowska-Mazuryk J, Matsumoto H, Sliwerska E, Glass J, Burmeister M, Brower KJ, Wojnar M . The CC genotype in HTR2A T102C polymorphism is associated with behavioral impulsivity in alcohol-dependent patients . Journal of Psychiatric Research . 46 . 1 . 44–49 . January 2012 . 21930285 . 3224206 . 10.1016/j.jpsychires.2011.09.001 .
  136. da Silva Junior FC, Araujo RM, Sarmento AS, de Carvalho MM, Fernandes HF, Yoshioka FK, Pinto GR, Motta FJ, Canalle R . December 2020. The association of A-1438G and T102C polymorphisms in HTR2A and 120 bp duplication in DRD4 with alcoholic dependence in a northeastern Brazilian male population . Gene Reports . 21 . 100889 . 10.1016/j.genrep.2020.100889 . 224859807.
  137. Land MA, Ramesh D, Miller AL, Pyles RB, Cunningham KA, Moeller FG, Anastasio NC . Methylation Patterns of the HTR2A Associate With Relapse-Related Behaviors in Cocaine-Dependent Participants . Frontiers in Psychiatry . 11 . 532 . 2020-06-10 . 32587535 . 7299072 . 10.3389/fpsyt.2020.00532 . free .
  138. Lemaire C, Cantineau R, Guillaume M, Plenevaux A, Christiaens L . Fluorine-18-altanserin: a radioligand for the study of serotonin receptors with PET: radiolabeling and in vivo biologic behavior in rats . Journal of Nuclear Medicine . 32 . 12 . 2266–2272 . December 1991 . 1744713 .
  139. Lundkvist C, Halldin C, Ginovart N, Nyberg S, Swahn CG, Carr AA, Brunner F, Farde L . [11C]MDL 100907, a radioligland for selective imaging of 5-HT(2A) receptors with positron emission tomography . Life Sciences . 58 . 10 . PL 187-PL 192 . 1996 . 8602111 . 10.1016/0024-3205(96)00013-6 .
  140. Johansen A, Hansen HD, Svarer C, Lehel S, Leth-Petersen S, Kristensen JL, Gillings N, Knudsen GM . The importance of small polar radiometabolites in molecular neuroimaging: A PET study with [<sup>11</sup>C]Cimbi-36 labeled in two positions . Journal of Cerebral Blood Flow and Metabolism . 38 . 4 . 659–668 . April 2018 . 29215308 . 5888860 . 10.1177/0271678x17746179 .
  141. Mintun MA, Sheline YI, Moerlein SM, Vlassenko AG, Huang Y, Snyder AZ . Decreased hippocampal 5-HT2A receptor binding in major depressive disorder: in vivo measurement with [18F]altanserin positron emission tomography . Biological Psychiatry . 55 . 3 . 217–224 . February 2004 . 14744461 . 10.1016/j.biopsych.2003.08.015 . 24849671 .
  142. Rosier A, Dupont P, Peuskens J, Bormans G, Vandenberghe R, Maes M, de Groot T, Schiepers C, Verbruggen A, Mortelmans L . Visualisation of loss of 5-HT2A receptors with age in healthy volunteers using [18F]altanserin and positron emission tomographic imaging . Psychiatry Research . 68 . 1 . 11–22 . November 1996 . 9027929 . 10.1016/S0925-4927(96)02806-5 . 32317795 .
  143. Meltzer CC, Smith G, Price JC, Reynolds CF, Mathis CA, Greer P, Lopresti B, Mintun MA, Pollock BG, Ben-Eliezer D, Cantwell MN, Kaye W, DeKosky ST . Reduced binding of [18F]altanserin to serotonin type 2A receptors in aging: persistence of effect after partial volume correction . Brain Research . 813 . 1 . 167–171 . November 1998 . 9824691 . 10.1016/S0006-8993(98)00909-3 . 21884218 .
  144. Adams KH, Pinborg LH, Svarer C, Hasselbalch SG, Holm S, Haugbøl S, Madsen K, Frøkjaer V, Martiny L, Paulson OB, Knudsen GM . A database of [(18)F]-altanserin binding to 5-HT(2A) receptors in normal volunteers: normative data and relationship to physiological and demographic variables . NeuroImage . 21 . 3 . 1105–1113 . March 2004 . 15006678 . 10.1016/j.neuroimage.2003.10.046 . 24403109 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "5-HT2A receptor".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.